NASDAQ:APLS

Apellis Pharmaceuticals Stock Signals

etoro logo Buy APLS
*Your capital is at risk
$41.03
+0 (+0%)
At Close: Jul 13, 2026

Latest Data & Signals Issued

Below are some of the latest signals issued for Apellis Pharmaceuticals Inc.

General

Signal Type Signal Value Data
Score 0.000 68 days ( -0.98 %
Last Price $41.03 0 %
Performance History
7 Days
$41.03 $41.03
0%
30 Days
$41.03 $41.03
0%
12 Mos
$19.44 $41.03
111.06%

5/18

Active Buy Signals

Specific Signals

Short Term
Net score: 29.73
Signal Type Signal Value Importance Data
High / Low N/A Very Low $41.03 - $41.03
Trend - 3 mos 0.290 % High Width: 0.600 %
Pred. range - 3 mos $41.08 - $41.33 Low 0.125 % - 0.725 %
Volume Direction Sell High Volume: 2 · Direction: 0
Pivot Short Sell Very Low May 06, 2026 - 46 days
RSI Short Pivot Signal Sell Very Low Jun 01, 2026 - 29 days
Short MA 3 mos Sell Low May 12, 2026 - 42 days
Long MA 3 mos Sell Medium Jun 23, 2026 - 14 days
Short/Long MA 3 mos Sell Medium Jun 23, 2026 - 14 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 54.33
Signal Type Signal Value Importance Data
Trend - 12 mos 77.10 % Very High Width: 100.80 %
Pred. range - 12 mos $40.16 - $80.65 High -2.11 % - 96.57 %
Short MA 12 mos Sell Very High Jun 02, 2026 - 28 days
Long MA 12 mos Buy Very High Mar 30, 2026 - 72 days
Short/Long MA 12 mos Buy Very High Apr 02, 2026 - 69 days
Pivot Long Sell Low May 06, 2026 - 46 days
RSI Long Pivot Signal Sell Low Jun 10, 2026 - 22 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT APELLIS PHARMACEUTICALS INC.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal ...
GOLDEN STAR
Ticker Change Signal Date
SRPT
$17.02
10.58% Jun 29
NMRK
$15.02
0.466% Jun 24
X
XMAX
$8.34
2.40% Jun 24
NESR
$25.07
12.49% Jun 23
CAG
$13.43
6.70% Jun 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE